Please amend claims 1-3, 5-8, 14 and 16 as follows:

1. (Amended) Recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) [CSF] protein having a sequence shown in Figure 1.

2. (Amended) Human GM-CSF protein having a specific activity of 1 x 10^7 units/mg in the bone marrow assay, a 15-26 kDa molecular weight and a sequence shown in Figure 1.

3. (Amended) Human GM-CSF protein as claimed in claim 2 which is recombinant GM-CSF protein.

~~5.~~ 4. (Amended) Human GM-CSF protein as claimed in any one of claims ~~1~~-3, wherein said protein comprises thr_{100} or ile_{100} [which has the amino acid sequence shown for CSF-thr in Fig. 1, or CSF-ile in Fig. 1, or CSF-G in Fig. 1].

~~6.~~ 5. (Amended) [A] Human GM-CSF protein as claimed in any one of claims 1-3, wherein said protein has an N-terminus consisting of ala or met-ala [which contains the amino acid sequence as shown in Fig. 1 commencing with Ala·Pro ... or wherein the amino acid sequence commencing Ala·Pro ... is proceeded by a methionine residue].

79

7. (Amended) [A] Human GM-CSF protein according to any one of claims 1-3, comprising at least one of the group consisting of ser_3, arg_{10}, ile_{36}, val_{43}, thr_{117} and gly_{127} [which is a CSF protein corresponding in amino acid sequence to a naturally occurring CSF, except that one or more amino acids has been added, substituted or removed without substantially affecting the biological activity of the natural CSF].

8. (Amended) [A] Human GM-CSF protein according to any one of claims 1-3, which is a CSF protein having the amino acid sequence of a natural CSF except that it is ~~proceeded~~ preceded by a methionine residue.

14. (Amended) A [pharmaceutical] composition comprising a human GM-CSF according to any one of claims 1-3, [or CSF according to claim 1 for use in therapy] in a pharmaceutically acceptable carrier.

16. (Amended) A [pharmaceutical] composition comprising a [recombinant] human GM-CSF according to any one of claims 1-3, prepared [according to the process of claim 12] by the steps comprising:

precipitating the GM-CSF protein with ammonium sulfate to form a pellet containing the ~~CSF~~ GM-CSF protein;

resuspending the pellet in a buffered solution at a pH in the range of about 6 to about 8;

80